Key result
The clot microstructure biomarker df identified a significant difference between patients with venous thromboembolism and non-VTE controls (P<0.001).
Why the study?
Does the biomarker of clot microstructure (df) differentiate patients with VTE from non-VTE patients and identify risk of recurrence?
Observational (n=129)
Does the biomarker of clot microstructure (df) differentiate patients with VTE from non-VTE patients and identify risk of recurrence?
The biomarker of clot microstructure (df) can significantly differentiate VTE from non-VTE patients and may help identify those at risk of recurrence.
This study compared patients with venous thromboembolism (VTE) to non-VTE patients using a biomarker of clot microstructure (df ) and clot formation time (TGP ). df was the only marker that identified a significant difference (P < 0·001) between the VTE (n = 60) and non-VTE cohorts (n = 69). The 'abnormal' clot microstructures in the VTE patients suggests either inadequate response to anticoagulant therapy or the presence of a procoagulant state not detected by other markers of coagulation (i.e., International Normalized Ratio). Furthermore, elevated values of df in first time VTE patients who later develop a secondary event indicates that df may identify those at risk of recurrence.
No takes yet. Share an insight, caveat, or question.
Lawrence et al. (2014) conducted an observational in Venous thromboembolism (n=129). Biomarker of clot microstructure (df) vs. Non-VTE patients was evaluated on Difference in clot microstructure (df) (p=<0.001). The clot microstructure biomarker df identified a significant difference between patients with venous thromboembolism and non-VTE controls (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: